Important milestone, today. IMU has announced that the first patients have received doses in the VAXINIA MAST trial. The Phase 1 MAST (metastatic advanced solid tumours) study evaluating the safety of novel cancer-killing virus CF33-hNIS (VAXINIA) has seen the first patients dosed in the intravenous (IV) and intratumoral (IT) cohorts of CF33-hNIS in combination with Pembrolizumab.

Imugene MD & CEO Leslie Chong said: “Having continued through the monotherapy dose escalation with safety and early positive signals, we’re eager to see VAXINIA used in combination with the well-known drug Pembrolizumab and see the potential benefit this could bring to patients. We’re setting an excellent pace with the trial and look forward to data and results in due course.”

Held in my SMSF